Yazar "Birinci, Şuayip" için PubMed İndeksli Yayın Koleksiyonu listeleme
-
COVID-19 clinical course and blood groups: Turkish population-based study
Dal, Mehmet Sinan; Ata, Naim; Altuntaş, Fevzi; Başcı, Semih; Yigenoğlu, Tuğçe Nur; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Tubitak Scientific & Technical Research Council Turkey, 2021)Background/aim: SARS-CoV-2 enters the cell through the binding of the S glycoprotein on the surface of the virus to the angiotensin-converting enzyme 2 (ACE-2) in the host cells and also SARS-CoV S protein binding to ACE-2 ... -
COVID-19 in hematopoietic cell transplant recipients
Altuntaş, Fevzi; Ata, Naim; Yigenoğlu, Tuğçe Nur; Başcı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Springernature, 2021)In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A ... -
The effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data
Özkan, Gülsüm; Ulusoy, Şükrü; Erdem, Yunus; Altun, Bülent; Yılmaz, Rahmi; Ata, Naim; Birinci, Şuayip (Taylor & Francis Inc, 2022)Aim The effect of hypertension (HT) and antihypertensive therapies such as renin-angiotensin-aldosterone system (RAAS) blockers on the disease course in COVID-19 patients is controversial. The purpose of this study was to ... -
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
Başcı, Semih; Ata, Naim; Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Sage Publications Ltd, 2020)Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ... -
The outcome of COVID-19 in patients with hematological malignancy
Yigenoğlu, Tuğçe Nur; Ata, Naim; Altuntaş, Fevzi; Başçı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Wiley, 2021)In this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 ... -
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
Başcı, Semih; Ata, Naim; Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Springer-Verlag Italia Srl, 2022)Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course ...